English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/212653
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMuñoz Sáez, Miguel-
dc.contributor.authorRosso González, M.-
dc.contributor.authorCoveñas, Rafael-
dc.date.accessioned2020-05-29T09:06:26Z-
dc.date.available2020-05-29T09:06:26Z-
dc.date.issued2019-
dc.identifierdoi: 10.3390/cancers11091258-
dc.identifiere-issn: 2072-6694-
dc.identifier.citationCancers 11(9): 1258 (2019)-
dc.identifier.urihttp://hdl.handle.net/10261/212653-
dc.descriptionThis article belongs to the Special Issue Hepatoblastoma and Pediatric Liver Tumors.-
dc.description.abstractHepatoblastoma (HB) is the most common malignant liver tumor that occurs during childhood. The prognosis of children with HB is favorable when a complete surgical resection of the tumor is possible, but for high-risk patients, the prognosis is much worse. New anti-HB strategies must be urgently developed. The undecapeptide substance P (SP) after binding to the neurokinin-1 receptor (NK-1R), regulates cancer cell proliferation, exerts an antiapoptotic effect, induces cell migration for invasion/metastasis, and triggers endothelial cell proliferation for neoangiogenesis. HB samples and cell lines overexpress NK-1R (the truncated form) and SP elicits HB cell proliferation. One of these strategies could be the use of non-peptide NK-1R antagonists. These antagonists exert, in a concentration-dependent manner, an antiproliferative action against HB cells (inhibit cell proliferation and induce the death of HB cells by apoptosis). NK-1R antagonists exerted a dual effect in HB: Decreased both tumor volume and angiogenic activity. Thus, the SP/NK-1R system is an important target in the HB treatment and NK-1R antagonists could act as specific drugs against HB cells. In this review, we update and discuss the use of NK-1R antagonists in the treatment of HB.-
dc.description.sponsorshipThis research was funded by “Programa XI: Financiación de Unidades de Excelencia de la Universidad de Salamanca” (Spain).-
dc.languageeng-
dc.publisherMultidisciplinary Digital Publishing Institute-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.subjectNK-1 receptor-
dc.subjectSubstance P-
dc.subjectHepatoblastoma-
dc.subjectAprepitant-
dc.subjectAntitumor-
dc.subjectApoptosis-
dc.subjectAngiogenesis-
dc.titleNeurokinin-1 receptor antagonists against hepatoblastoma-
dc.typeartículo-
dc.relation.publisherversionhttps://doi.org/10.3390/cancers11091258-
dc.date.updated2020-05-29T09:06:26Z-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/-
dc.contributor.funderUniversidad de Salamanca-
dc.relation.csic-
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
neurokin.pdf931,02 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.